Article Text

Download PDFPDF

Mitomycin C for pterygium: long term evaluation
  1. F Raiskup,
  2. A Solomon,
  3. D Landau,
  4. M Ilsar,
  5. J Frucht-Pery
  1. Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel
  1. Correspondence to: Professor Dr J Frucht-Pery Department of Ophthalmology, Hadassah University Hospital, POB 12000, 91120 Jerusalem, Israel;


Aim: To evaluate long term complications after pterygium excision with mitomycin C (MMC) application.

Design: Prospective non-comparative interventional case series.

Participants: Ninety nine patients who underwent pterygium surgery and participated in a controlled study for efficacy of MMC for pterygium surgery between 1989 and 1994.

Methods: Patients who were located and agreed to come for examination underwent a complete eye examination. The bare sclera area, in particular, was examined for possible complications. The main outcome measures were anatomical findings in area of MMC application.

Results: Forty three eyes of 43 patients were examined. Sixty three per cent of patients had pterygium surgery with intraoperative application of 0.02% MMC for 5 minutes and 37% of patients received MMC 1% or 2% drops four times daily for 2 weeks postoperatively. In three patients, pterygium recurred within 18 months. The only complication was mild conjunctival avascularity in areas of pterygium excision in 30% of patients.

Conclusion: Long term evaluation revealed that the use of MMC in pterygium surgery is safe, but for a strict selection of patients, controlled use of MMC and long term follow up are required.

  • MMC, mitomycin C
  • Mitomycin C
  • pterygium
  • MMC, mitomycin C
  • Mitomycin C
  • pterygium

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors state that they have no propriety, financial, or any other interest in any device, material, or company described or mentioned in the article.

Linked Articles

  • BJO at a glance
    Creig Hoyt